Evidence map›Paper›PMID 40265061›Full record

ArticleFrontiers in public health2025

Changes in the prevalence of hepatitis B virus and its related factors in Inner Mongolia between 2006 and 2020.

Xuejie Ding, Zhongbing Zhang, Cheng Li, Hui Song, Shuna Ding, Yu Zhou, Xianyun Ren, Fei Hou, Xia Wen, Chunyan Li and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xuejie Ding *School of Public Health, Inner Mongolia Medical University, Hohhot, China.
Zhongbing Zhang *Inner Mongolia Center for Disease Control and Prevention, Hohhot, China.
Cheng LiInner Mongolia Center for Disease Control and Prevention, Hohhot, China.
Hui SongNorth China University of Science and Technology Affiliated Hospital, Tangshan, China.
Shuna DingSchool of Public Health, BaoTou Medical College, Baotou, China.
Yu ZhouSchool of Public Health, Inner Mongolia Medical University, Hohhot, China.
Xianyun RenCenter for Disease Control and Prevention of Hohhot, Hohhot, China.
Fei HouCenter for Disease Control and Prevention of Baotou, Baotou, China.
Xia WenCenter for Disease Control and Prevention of Hulunbeier, Hulunbeier, China.
Chunyan LiCenter for Disease Control and Prevention of Hinggan League, Hinggan League, China.
Libo WangCenter for Disease Control and Prevention of Tongliao, Tongliao, China.
Junqing MaCenter for Disease Control and Prevention of Chifeng, Chifeng, China.
Liwei ZhangCenter for Disease Control and Prevention of Xilingol League, Xilingol League, China.
Yan WangCenter for Disease Control and Prevention of Erdos, Erdos, China.
Shuling WangCenter for Disease Control and Prevention of Wuhai, Wuhai, China.
Chunmei GengCenter for Disease Control and Prevention of Bayannur, Bayannur, China.
Shan WuCenter for Disease Control and Prevention of Alxa, Alxa, China.
Junmei GuCenter for Disease Control and Prevention of Ulanqab, Ulanqab, China.
Xiaoling TianInner Mongolia Center for Disease Control and Prevention, Hohhot, China.
Qingbin LuLaboratory Science and Technology, School of Public Health, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to compare the prevalence of serum hepatitis B virus (HBV) markers in Inner Mongolia between 2006 and 2020. Methods: The same sampling process was used in investigations conducted in 2006 and 2020. A multi-stage stratified random sampling method was used to select subjects aged 1-60 years old from 12 cities in Inner Mongolia. Blood samples were collected to detect serological HBV markers including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (HBcAb). The prevalence of serum biomarkers of hepatitis B, standardized by age and sex, was analyzed and compared between 2006 and 2020. Results: There were 6,304 subjects in 2006 and 6,500 in 2020. The prevalence of HBsAg was higher in 2006 than in 2020 (standardized 4.11% vs. 2.75%, Conclusion: The prevalence of HBsAg decreased significantly from 2006 to 2020 in Inner Mongolia, suggesting that the Hep B vaccine has made remarkable progress in safeguarding the population against hepatitis B infection.

Indexed as

Hepatitis BHepatitis B virusAdolescentAdultBiomarkersChildChild, PreschoolChinaFemaleHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHumansInfantMaleMiddle AgedBiomarkersHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesChinacross-sectional studyHBV prevalencehepatitis B vaccineinfectious disease

Identifiers

PMID40265061
PMCPMC12011829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.